Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Bile Duct Cancer

Lisata Therapeutics, Inc.Small moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Bile Duct Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Lisata Therapeutics, Inc.
Phase 2BB
Dfn-15
Seoul National University Hospital
Phase 4B
Pembrolizumab
Imugene Limited
Phase 2B
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2B
N-BUTYL CYANOACRYLATE
Minia University
Phase 3B

View all 30 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →